Showing 1 - 8 of 8
Persistent link: https://www.econbiz.de/10012118086
Persistent link: https://www.econbiz.de/10010478092
Persistent link: https://www.econbiz.de/10008699793
Persistent link: https://www.econbiz.de/10008909815
Statistical models in econometrics, biology, and most other areas, are not expected to be correct, and often are not very accurate. The choice of a model for the analysis of data depends on the purpose of the analysis, the relation between the data and the model, and also on the sample or data...
Persistent link: https://www.econbiz.de/10010949111
We consider the classical problem of selecting the best of two treatments in clinical trials with binary response. The target is to find the design that maximizes the power of the relevant test. Many papers use a normal approximation to the power function and claim that Neyman allocation that...
Persistent link: https://www.econbiz.de/10008865883
Phase I clinical trials are conducted in order to find the maximum tolerated dose (MTD) of a given drug from a finite set of doses. For ethical reasons, these studies are usually sequential, treating patients or group of patients with the best available dose according to the current knowledge....
Persistent link: https://www.econbiz.de/10008684445
The continual reassessment method (CRM) is a model-based design that aims at finding the maximum tolerated dose (MTD) of a given drug. As the CRM is a model-based technique, its use may be restricted to cases where the true dose-response curve satisfies its underlying working model. Shen and...
Persistent link: https://www.econbiz.de/10010576139